Analysis: J&J Q1 clouded on stent worries.

Publication: UPI Health Business

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2007 United Press International

Byline: STEVE MITCHELL

WASHINGTON, April 17 (UPI) -- Johnson and Johnson's first quarter earnings soundly beat Wall Street's expectations, but analysts expressed concern about the company going forward due to the safety issues revolving around anemia and stent products.

Bank of America analyst Glenn Novarro called the performance "a statement quarter" that reflects the company's broad portfolio.

However, Novarro questioned J&J's failure to update its 2007 earnings guidance.

"We note that investors will be paying particular attention to this update, given the recent concerns over Procrit, the relatively slow launch of Invega and lingering concerns over the contracting drug-eluting...

Read the full article for free courtesy of your local library.